NASDAQ:OTIC - Otonomy Stock Price, Price Target & More

Otonomy trades on the NASDAQ under the ticker symbol "OTIC."

Otonomy Inc (NASDAQ:OTIC) released its quarterly earnings data on Thursday, March, 8th. The biopharmaceutical company reported ($0.62) EPS for the quarter, beating analysts' consensus estimates of ($0.67) by $0.05. The biopharmaceutical company had revenue of $0.27 million for the quarter, compared to the consensus estimate of $0.46 million. Otonomy had a negative return on equity of 58.60% and a negative net margin of 6,316.88%. The business's revenue was down 1.1% on a year-over-year basis. View Otonomy's Earnings History.

4 analysts have issued twelve-month price targets for Otonomy's stock. Their predictions range from $8.00 to $15.00. On average, they anticipate Otonomy's stock price to reach $10.00 in the next twelve months. This suggests a possible upside of 177.8% from the stock's current price. View Analyst Ratings for Otonomy.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Otonomy in the last year. There are currently 1 sell rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Otonomy saw a decrease in short interest during the month of June. As of June 29th, there was short interest totalling 727,991 shares, a decrease of 44.9% from the June 15th total of 1,321,378 shares. Based on an average trading volume of 576,927 shares, the short-interest ratio is currently 1.3 days. Approximately 2.8% of the company's shares are sold short. View Otonomy's Current Options Chain.

Some companies that are related to Otonomy include Evelo Biosciences (EVLO), Achillion Pharmaceuticals (ACHN), Syros Pharmaceuticals (SYRS), American Brivision (Holding) (ABVC), ProMetic Life Sciences (PFSCF), Albireo Pharma (ALBO), Concert Pharmaceuticals (CNCE), Savara (SVRA), Ra Pharmaceuticals (RARX), MediciNova (MNOV), Xeris Pharmaceuticals (XERS), Mersana Therapeutics (MRSN), Bellicum Pharmaceuticals (BLCM), Clementia Pharmaceuticals (CMTA) and Clearside Biomedical (CLSD).

News articles about OTIC stock have trended somewhat positive this week, according to Accern Sentiment. The research firm scores the sentiment of press coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Otonomy earned a news impact score of 0.12 on Accern's scale. They also gave headlines about the biopharmaceutical company an impact score of 47.75 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near term.

Shares of OTIC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of OTIC stock can currently be purchased for approximately $3.60.

Otonomy has a market capitalization of $110.08 million and generates $1.24 million in revenue each year. The biopharmaceutical company earns $-90,130,000.00 in net income (profit) each year or ($2.97) on an earnings per share basis. Otonomy employs 53 workers across the globe.

Otonomy's mailing address is 4796 EXECUTIVE DRIVE, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 619-323-2200 or via email at [email protected]